Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance by Bergval, Indra L. et al.
Resistant mutants of Mycobacterium tuberculosis selected in vitro
do not reﬂect the in vivo mechanism of isoniazid resistance
Indra L. Bergval*, Anja R. J. Schuitema, Paul R. Klatser and Richard M. Anthony
KIT Biomedical Research, Royal Tropical Institute, Amsterdam, The Netherlands
Received 5 March 2009; returned 21 April 2009; revised 11 May 2009; accepted 11 June 2009
Objectives: The high prevalence of isoniazid-resistant Mycobacterium tuberculosis is often explained
by a high mutation rate for this trait, although detailed information to support this theory is absent.
We studied the development of isoniazid resistance in vitro, making use of a laboratory strain of
M. tuberculosis.
Methods: Spontaneous isoniazid-resistant mutants were characterized by molecular methods allowing
identiﬁcation of the most commonly encountered resistance-conferring mutations. Additionally, we
determined the in vitro mutation rates for isoniazid and rifampicin resistance, and characterized the
genome of a triple-resistant strain.
Results: Results conﬁrm that the in vitro mutation rate for isoniazid resistance (3.2310
27 mutations/
cell division) is much higher than the rate for rifampicin resistance (9.8310
29 mutations/cell division).
However, in the majority of the in vitro mutants katG was partially or completely deleted and neither of
the two most common in vivo mutations, katG-S315T or inhA-C(-)15T, were found in 120 isogenic
mutants. This implies that clinically prevalent resistance mutations were present in <0.8% of isoniazid-
resistant strains selected in vitro (95% CI 0%–2.5%). The triple-resistant strain had acquired isoniazid
resistance via a 49 kbp deletion, which included katG. Apart from previously identiﬁed resistance-
conferring mutations, three additional point mutations were acquired during sequential selection
steps.
Conclusions: These outcomes demonstrate that the in vivo mechanism of isoniazid resistance is not
reﬂected by in vitro experiments. We therefore conclude that the high in vitro mutation rate for isonia-
zid resistance is not a satisfactory explanation for the fact that isoniazid monoresistance is signiﬁ-
cantly more widespread than monoresistance to rifampicin.
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Introduction
Although the global incidence of tuberculosis (TB) is declining,
drug resistance is rapidly emerging and spreading.
1 Insufﬁcient
control measures have led to a drastic increase in the prevalence
of drug-resistant strains and, more importantly, the degree of
drug resistance; in certain high-burden countries the nature of
multidrug-resistant TB (MDR-TB) has rapidly evolved from
incidental to epidemic.
1
The production of new and more effective antibiotics par-
tially addresses this problem, but without a more detailed
comprehension of the molecular mechanisms that lead to suc-
cessful (M)DR strains, these new compounds may also be
quickly rendered ineffective by the generation of extensively
drug-resistant TB (XDR-TB).
Isoniazid and rifampicin are the two most commonly used
anti-TB drugs and the backbone of any successful TB treatment
programme. MDR-TB is consequently deﬁned as TB that is
resistant to at least isoniazid and rifampicin. Monoresistance to
isoniazid is signiﬁcantly more prevalent than monoresistance to
rifampicin and MDR-TB; based on the most recent data it is
estimated that 13.3% of all TB cases globally involve isoniazid
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1
Shortly after the introduction of isoniazid in the 1950s, the
ﬁrst resistant Mycobacterium tuberculosis mutants were isolated
and it was observed that many of these strains had reduced cata-
lase activity.
2 It was ﬁrst assumed that deletion of katG, coding
for the only identiﬁed catalase–peroxidase in M. tuberculosis,
was the main mechanism responsible for resistance to isoniazid.
3
However, subsequent studies demonstrated that, although confer-
ring high levels of resistance, this is not the primary mechan-
ism.
4–7Although any mutation reducing KatG activity results in
resistance, relatively few mutations in katG account for the
majority of isoniazid resistance in clinical isolates; resistance to
isoniazid is primarily conferred by the mutations katG-S315T
(45%–75%) and inhA-C(-)15T (15%–25%).
8–13
Biochemical and in vitro studies have shown that the most
prevalent mutant, katG-S315T, still retains a signiﬁcant part of
its catalase activity,
7,14–17 which appears to be sufﬁcient for the
preservation of virulence.
18,19 Strains carrying this mutation typi-
cally have an intermediate (1–5 mg/L) level of resistance to iso-
niazid,
11,15,20,21 since KatG has reduced abilities to activate
isoniazid, but has not completely lost this function. Mutations in
the regulatory region of inhA usually lead to a low-level
resistance (0.2–1.0 mg/L).
15,21
Mutations that lead to complete loss of function of KatG,
such as deletions, insertions or other frameshifts, are found in a
small proportion of the isoniazid-resistant strains.
22 On average,
partial or complete katG deletion mutants are reported in only
 5% of resistant isolates,
13,15,20,23,24 but higher proportions have
been reported on occasion.
5,6 Additionally, strains with isoniazid
resistance due to deletion of the katG gene are less likely to be
clustered than strains with the katG-S315T mutation, a mutation
signiﬁcantly associated with successful dissemination.
12,13,25,26
Isolates resistant due to inactivation of KatG often have
additional mutations in the regulatory region or coding sequence
of ahpC, coding for an alkylhydroperoxidase.
27,28 Originally,
researchers assumed these mutations were alternative mechan-
isms of isoniazid resistance,
29,30 but subsequent studies showed
that the majority of the mutations in ahpC or the intergenic
region oxyR-ahpC were compensating for the loss of katG
function.
31,32
It is frequently assumed that the mutation rate for isoniazid
resistance is  100 times higher than for rifampicin and, conse-
quently, that isoniazid resistance precedes resistance to rifampi-
cin in the development of MDR-TB. However, there are no
empirical grounds for these assumptions. We therefore studied
the emergence of isoniazid resistance in vitro, making use of
well-characterized M. tuberculosis laboratory strains. We deter-
mined the in vitro mutation rate to isoniazid and characterized
spontaneous isoniazid-resistant mutants by sequencing, multi-
plex ligation-dependent probe ampliﬁcation (MLPA)
33 and
comparative genome hybridization (CGH).
Materials and methods
Growth of bacteria
The M. tuberculosis parent strains that all experiments were
conducted with, MTB72 (ATCC 35801) and H37Rv (ATCC 27294),
were initially susceptible to all antimicrobials used in this study.
Bacteria were cultured in Middlebrook medium 7H9 (Difco, BD,
Sparks, MD, USA), supplemented with oleic acid/albumin/dextrose/
catalase (OADC Enrichment, BD, Sparks, MD, USA), in a shaking
incubator at 378C. A liquid starting culture was made by inoculating
pure colonies from Lo ¨wenstein–Jensen or Coletsos slopes into
10 mL of culture medium. When these cultures reached the logarith-
mic growth phase, 0.5 mL was transferred to 9.5 mL of fresh, non-
selective medium and bacteria were cultured until mid-logarithmic
growth. Oxidative stress was applied by addition of H2O2 (31% sol-
ution Ultrapur, Merck KGaA, Darmstadt, Germany) at a subinhibi-
tory concentration of 50 mM, 24 h before the bacteria were
harvested. All procedures with live mycobacteria were performed in
a Biosafety Level III laboratory.
Growth in macrophages
THP-1 cells. Human macrophage-like THP-1 cells (ATCC TIB-202)
were grown in 8 mL of RPMI 1640 medium supplemented with 5%
fetal bovine serum, 1% HEPES and 1% L-glutamine (all from
Gibco, Invitrogen, Breda, The Netherlands). The cells were grown
in 75 cm
2 ﬂasks at 378C in a humidiﬁed chamber with a 5% CO2
atmosphere. When a density of  1 10
6 cells/mL was reached, cells
were treated with 16 nM phorbol 12-myristate 13-acetate (PMA;
Sigma–Aldrich Chemie, Zwijndrecht, The Netherlands). After 1 h,
M. tuberculosis bacteria were added and after 5 h the PMA and bac-
teria that were not phagocytosed were washed away with medium
twice.
M. tuberculosis. Log-phase cultures of M. tuberculosis strain
MTB72 were allowed to stand for 5 min and then the upper 500 mL
was ﬁltered with a 5 mm ﬁlter (Millipore). After ﬁltration, the con-
centration of the dispersed bacterial suspensions was determined by
measuring the absorbance at 420 nm, an A420 of 0.15 corresponding
to 1 10
8 bacteria/mL. Bacteria were added to the macrophages in
such a way that a multiplicity of infection of  1/10 was maintained.
An acid-fast stain was made and analysed by light microscopy
(magniﬁcation: 100) in order to determine if bacteria were properly
associated with the macrophages.
Selection of isoniazid-resistant mutants. In three experiments,
intracellular isoniazid-resistant bacteria were selected by addition of
1 mg/L isoniazid to the ﬂasks after 3 days growth of macrophagesþ
bacteria. After 4 h of incubation with isoniazid, the supernatant was
discarded and cells were washed with fresh medium. Macrophages
were scraped off the bottom of the ﬂask with a cell scraper and
taken up in 2 mL sterile water in a new tube. The macrophages were
disrupted by application of osmotic stress and sonication in a water
bath, and bacteria were subsequently plated on solid Middlebrook
medium (MB7H11) containing 1 mg/L isoniazid.
In one experiment, the pre-selection of resistant mutants in the
cells was omitted and after disruption of the macrophages an aliquot
of the bacteria was used for determination of cfu. From this exper-
iment, the mutation frequency in macrophages was calculated.
Proportion of mutants
To determine the mutation frequency (i.e. the proportion of resistant
mutants), four 0.5 mL aliquots of log-phase cultures were plated
onto solid MB7H11 medium (Difco, BD, Sparks, MD, USA) con-
taining 0.4, 1.0 or 20 mg/L isoniazid (Sigma–Aldrich Chemie).
Serial dilutions of the cultures were plated on non-selective medium
to determine the cfu present. The mutation frequency was calculated
by dividing the number of resistant colonies by the cfu plated. From
each experiment, a number of resistant mutants were picked from
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molecular characterization.
Fluctuation assay
The mutation rates (i.e. the chance of a mutation occurring per
generation) for isoniazid and rifampicin were determined by
performing a ﬂuctuation assay, making use of the p0-method.
34
A 10 mL starting culture was prepared by inoculating strain
MTB72 from a slope, to minimize the presence of spontaneous
mutants. When bacterial growth reached mid-logarithmic phase, the
culture was vortexed vigorously to homogenize the bacterial suspen-
sion. Clumped cells were allowed to settle for 3 min and 55 new
1 mL cultures were made by transferring 1 mL of this cell suspen-
sion ( 1000 bacteria) to a 2 mL screwcap tube containing 1 mL of
MB7H9 mediumþOADC. Two to three sterile glass beads were
added to each culture, to ensure a continuous homogeneous suspen-
sion. The 1 mL cultures were incubated in a shaking incubator at
378C for  10 generations ( 8 days), ensuring a  1000-fold
increase in cell number. The cultures were then centrifuged at
5000 g for 8 min and 850 mL of supernatant was discarded. For
each culture the remaining 150 mL was plated in one well of a
square 25-well replica plate (Greiner, Germany) containing 3 mL of
MB7H11 supplemented with either 8 mg/L rifampicin (Sigma–
Aldrich Chemie) or 1.0 mg/L isoniazid. The number of cfu plated in
each well was estimated by making serial dilutions of the ﬁve
remaining 1 mL cultures and plating onto non-selective MB7H11.
The two 25-well replica plates were allowed to dry in a biosafety
laminar ﬂow cabinet, until all liquid was absorbed into the solid
medium. The plates were then sealed and incubated at 378C. After
3–4 weeks incubation, the proportion of squares without growth
was counted and the mutation rate was calculated.
34
DNA isolation
Separate mutant colonies, selected on isoniazid-containing solid
medium, were picked and suspended in 150 mL of Tris/EDTA
buffer containing 1% Triton X-100 (BDH Laboratory Supplies,
Poole, England) and then heated at 958C for 30 min. After lysis,
cells were centrifuged at 5000 g for 3 min and 130 mL of the super-
natant was collected as a DNA sample.
For the experiment using pooled isolates, four separate colonies
were suspended in a single tube and DNA was extracted
simultaneously.
PCR and sequencing
A 233 bp fragment, surrounding codon 315 of katG, was ampliﬁed
from selected isolates by PCR using forward primer katG-315_FW
50-CATGAACGACGTCGAAACAG-30 and reverse primer
katG-315_RV 50-CGAGGAAACTGTTGTCCCAT-30. In addition, a
300 bp fragment of katG surrounding codon 463 was ampliﬁed
using forward primer katG-463_FW 50-TCCCGTTGCGAG
ATACCTT-30 and reverse primer katG-463_RV 50-AGGGTGCG
AATGACCTTG-30. Isolates were scored as DkatG if one or both of
the PCR products were absent. From a proportion of the strains that
were positive for the katG-315 PCR, the PCR fragment was
sequenced in both directions according to protocols previously
published.
35
From another subselection of our isoniazid-resistant isolates, a
251 bp fragment spanning the intergenic region of oxyR-ahpC was
ampliﬁed and sequenced, using forward primer oxyR-ahpC_FW
50-TGCTGAACCACTGCTTTGC-30 and reverse primer
oxyR-ahpC_RV 50-GGTCACCGCCGATGAGAGC-30.
Results of all PCRs were analysed by agarose gel electrophoresis
using a 2% agarose gel (Multi-Purpose agarose, Roche Diagnostics
GmbH, Mannheim, Germany).
MLPA
M. tuberculosis-speciﬁc MLPA was performed as previously
published,
33 except in the present study only four probes were
included (Table 1), allowing results to be easily interpreted on an
agarose gel. The 16S rRNA probe (202 bp) targets a region speciﬁc
for members of the MTB complex and was used as internal control.
Probes katG-315 (160 bp) and inhA-15 (178 bp) identify the two
most prevalent isoniazid resistance-conferring mutations. Probe
katG-463 targets a point mutation in codon 463 of katG speciﬁc for
principal genotypic groups (PGGs) 2 and 3 that was present in all
strains used in this study. The absence of the katG-463 or katG-315
products identiﬁed a deletion of these regions.
CGH
Strain RB14, a rifampicin- and rifabutin-resistant isolate derived
from MTB72,
35,36 was plated on solid medium containing 20 mg/L
isoniazid. Upon growth of isoniazid-resistant mutants, 13 colonies
were picked, puriﬁed and analysed by PCR and MLPA, as
described in this study. Seven out of 13 (54%) were negative for
both the katG-315 and the katG-463 PCR, indicating a substantial
deletion of the katG region. We selected one of these deletion
mutants of RB14, RB14H5, for further analysis. In order to deter-
mine the exact size of the deletion, the genomes of strain RB14H5
and MTB72, its wild-type parent, were compared by CGH
(NimbleGen CGH Whole-Genome Tiling Arrays, Roche
NimbleGen, Madison, WI, USA). DNA was extracted from liquid
cultures and processed, puriﬁed and shipped according to the com-
pany’s requirements. Data obtained from the CGH experiment was
interpreted and analysed with SignalMap v1.9 and Microsoft
Excel. Primers were designed to amplify likely regions of
Table 1. MLPA probes used in this study to screen isoniazid-resistant mutants
MLPA probe Target Length of ligated probes Phenotype
16S rRNA 16S rRNA gene 202 bp member of MTB complex
katG-315 katG codon 315 ACC 160 bp isoniazid-resistant via katG-S315T
inhA-15 inhA (-)15 ‘T’ allele 178 bp isoniazid-resistant via inhA-C(-)15T
katG-463 katG codon 463 CGG 319 bp PGG 2 or 3
Indicated are the name of the probe, the region or point mutation it targets, the length of the ligated probes and the phenotype that is associated with the point
mutation.
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cycle sequencing [Table S1, available as Supplementary data at
JAC Online (http://jac.oxfordjournals.org/)].
Results
Deletions in katG are the most common mechanism
of resistance to isoniazid in vitro
Two initial independent experiments with MTB72 were
performed, using 20 mg/L isoniazid to select resistant mutants.
Mutation frequencies of 4.40 10
26 and 7.56 10
26 were
measured, and PCR assays targeting the regions ﬂanking
codons 315 and 463 of katG identiﬁed deletions in 4/20 and
18/20 mutants, respectively (Table 2). None of the mutants
with an intact katG gene carried a mutation, as determined
by sequencing, except for one strain that had acquired a
TGG(W)!CGG(F) mutation in codon 321. Deletions in katG
were conﬁrmed by MLPA, as well as the absence of typical
mutations katG-S315T or inhA-C(-)15T in all the characterized
mutants.
We hypothesized that the high mutation frequencies and
domination of katG deletions over isoniazid resistance-
conferring mutations were either due to the absence of signiﬁ-
cant oxidative stress in vitro or the concentration of isoniazid
used. To test the ﬁrst hypothesis, the experiment was repeated
after exposure to 50 mM H2O2, in an attempt to select against
the occurrence of katG deletions in favour of clinically relevant
mutations. The mutation frequency was comparable to that
obtained in previous results (3.6 10
26, see Table 2) and 17/20
(85%) selected mutants had a deletion in katG. None of the ana-
lysed strains had acquired resistance mutations in katG-315 or
inhA-(-)15.
We then lowered the concentration of isoniazid to 1 mg/L.
Again, two independent experiments were performed, both
resulting in average to high proportions of katG deletion mutants
(13/37 and 15/20) and none of the targeted clinically prevalent
mutations in 57 colonies analysed. The mutation frequencies
were 1.78 10
26 and 4.17 10
26, respectively. Addition of H2O2
to the medium slightly increased the mutation frequency to
1.60 10
25, but the majority (14/20) of the selected mutants had
still acquired a deletion in katG (Table 2).
Five independent experiments were also conducted to deter-
mine the mutation frequency for rifampicin, resulting in an
average mutation frequency of 6.86 10
28 using 8 mg/L rifampi-
cin (Table 2). This was 43.4 times lower than the average
mutation frequency observed with 1 mg/L isoniazid. In addition,
ﬂuctuation assays were performed to determine the mutation
rates for isoniazid and rifampicin. The estimated mutation rate
for 1 mg/L isoniazid was 3.2 10
27 mutations/cell division, 32.3
times higher than the estimated rate for 8 mg/L rifampicin
(9.81 10
29 mutations/cell division, Table 2).
Less than 1% of in vitro selected isoniazid-resistant mutants
carry a clinically prevalent mutation
Being unsuccessful in our attempt to select for isoniazid-
resistant strains with either of the two most clinically prevalent
mutations, we decided to screen a larger pool of isoniazid-
resistant mutants derived from MTB72, in order to estimate the
prevalence of the most common clinical mutations in vitro.W e
used the methods described above to select isoniazid-resistant
mutants with 0.4 mg/L isoniazid.
The mutation frequency was 8.02 10
26 (Table 3) and an
initial characterization of 29 mutants showed that 28% (8/29,
Table 3) had acquired a deletion in katG. To increase the chance
Table 2. Characterization of the spontaneous isoniazid-resistant mutants derived from strain MTB72
Antibiotic concentration Selection condition Mutation frequency Mutation rate No. of DkatG (%) No. of targeted mutations
20 mg/L INH — 7.56 10
26 — 18/20 (90%) 0/20
— 4.40 10
26 — 4/20 (20%) 0/20
þH2O2 3.60 10
26 — 17/20 (85%) 0/20
1 mg/L INH — 4.17 10
26 — 15/20 (75%) 0/20
— 1.78 10
26 — 13/37 (35%) 0/37
þH2O2 1.60 10
25 — 14/20 (70%) 0/20
þTHP1 1.84 10
26 — 5/24 (21%) 0/24
þTHP1þINH — — 1/10 (10%) 0/10
þTHP1þINH — — 0/5 (0%) 0/5
þTHP1þINH — — 6/20 (30%) 0/20
1 mg/L INH — 2.98 10
26a 3.20 10
27 ——
8 mg/L RIF — 6.86 10
28b 9.81 10
29 ——
INH, isoniazid; RIF, rifampicin; THP1, macrophage; MTB, M. tuberculosis.
The concentration of isoniazid was the concentration in the solid medium on which the bacteria were selected. The selection conditions are additional criteria
to select against DkatG mutants, in an attempt to favour the selection of clinically relevant mutants. Mutation frequency is the proportion of mutants.
Mutation rate is the estimated number of mutants per generation. No. of DkatG is the number of katG deletion mutants (of the characterized mutants). No. of
targeted mutations is the number of katG-S315T or inhA-C(-)15T found in the characterized mutants.
aAverage of data depicted in this table.
bAverage of ﬁve independent experiments.
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were picked from the original plates (0.4 mg/L isoniazid) and
plated in duplicate on plates containing 0.4 mg/L isoniazid and
2.0 mg/L isoniazid. Thirty colonies were picked that grew on
0.4 mg/L isoniazid but showed no growth on 2.0 mg/L isoniazid
and, thus, had an MIC between 0.4 and 2.0 mg/L isoniazid. Of
these 30 selected mutants, three (10%) had acquired deletions in
katG (Table 3). No mutations were found in katG-315 or
inhA-(-)15 by MLPA, but sequencing of katG from 10 of these
low-MIC mutants with intact katG revealed an ACT(T)!ATT(I)
mutation in codon 271 of katG in one of the strains.
From the panel of mutants selected with 0.4 mg/L isoniazid,
an additional subpopulation with an MIC.2.0 mg/L was ana-
lysed by MLPA, targeting the inhA-15 and katG-315 mutant
alleles. In order to facilitate analysis, mutant colonies were
pooled in sets of four before DNA was extracted and a total of
120 mutants were screened in this fashion. The suitability of the
method for detecting a single mutant in a mixed sample using
MLPA was conﬁrmed by analysis of artiﬁcial mixtures made
with wild-type M. tuberculosis DNA and DNA from clinical
strains carrying either the katG-S315T or inhA-C(-)15T mutation
(Figure 1). We were unable to measure the number and percen-
tage of DkatG mutants with this method, since samples were
mixtures of four colonies and only samples in which all four
colonies had a deletion in katG would be detected. No mutations
were found in these 120 isoniazid-resistant in vitro mutants,
indicating that the prevalence of clinically relevant mutations
[katG-S315T or inhA-C(-)15T] in vitro is ,0.8% (95% CI
0%–2.5%), under the conditions described (Table 3).
Representative experiments were also performed with model
strain H37Rv. Selection of spontaneous resistant mutants
with 0.4 mg/L isoniazid resulted in a mutation frequency of
2.3 10
26. From the resistant mutants, a subselection was made
of strains with an MIC between 0.4 and 2.0 mg/L isoniazid.
MLPA analysis of 30 of these selected strains showed that 3.3%
(1/30) had acquired a deletion in katG, but no mutations were
detected in katG-315 or inhA-(-)15. This indicates that also for
strain H37Rv ,3.3% of the isoniazid-resistant H37Rv mutants
carried a clinical mutation.
No adaptive mutations were found in the oxyR-ahpC
intergenic region of a random selection of DkatG mutants
In order to exclude the possibility that the high prevalence of
DkatG mutants in our experiments was due to the acquisition of
mutations in the oxyR-ahpC intergenic region, we sequenced a
251 bp fragment spanning the oxyR-ahpC intergenic region of a
selection of our MTB72-derived isoniazid-resistant mutants.
This panel of strains represented the different isoniazid concen-
trations and additional selection conditions used in this study,
and all strains had acquired deletions in various regions of katG.
In total, we screened 21 DkatG mutants for adaptive mutations
in oxyR-ahpC. The sequence of all analysed mutants was identi-
cal to that of the wild-type parent MTB72, indicating that none
of the mutants had acquired mutations in this region.
In vitro-selected DkatG mutant has a 49 kbp deletion, but is
viable in vitro
The genomes of MTB72 and RB14H5 were screened by CGH,
in order to obtain information about the mutations that RB14H5
acquired during the sequential selection steps. Puriﬁed DNA
from both strains was compared with the sequence of strain
CDC1551 (GenBank AE000516). The CGH data indicated a
large deletion in the RB14H5 genome, compared with that of
MTB72 [Figure S1, available as Supplementary data at JAC
Online (http://jac.oxfordjournals.org/)]. A PCR with primers tar-
geting the ﬂanking regions conﬁrmed that a 49 kbp fragment
300
200
100
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Figure 1. Agarose gel showing separation of MLPA products. Samples
shown are artiﬁcial mixtures made with DNA from isoniazid-resistant
clinical isolates and DNA from wild-type strain MTB72. From top to
bottom, bands represent ampliﬁed probes targeting katG-L463R (319 bp),
16S rRNA (202 bp) and inhA-C(-)15T (178 bp, lanes 1–3) or katG-S315T
(160 bp, lanes 4–6). Lane 1, 100% inhA-C(-)15T mutant; lane 2, 10%
inhA-C(-)15T mutantþ90% wild-type; lane 3, 20% inhA-C(-)15T
mutantþ80% wild-type; lane 4, 20% katG-S315T mutantþ80% wild-type;
lane 5, 10% katG-S315T mutantþ90% wild-type; lane 6, 100% katG-S315T
mutant; lane 7, 100% wild-type. M denotes a 100 bp marker, numbers on the
ﬁrst three bands correspond to the respective sizes (in bp).
Table 3. Characterization of MTB72-derived isoniazid-resistant mutants initially selected with
0.4 mg/L isoniazid
Acquired MIC Mutation frequency No. of DkatG (%) No. of targeted mutations (%)
Undeﬁned 8.02 10
26 8/29 (28%) 0/29 (,3.5%)
0.4,MIC,2.0 — 3/30 (10%) 0/30 (,3.3%)
MIC.2.0
a — — 0/120 (,0.8%)
A subdivision of two groups of mutants was made on the basis of their acquired isoniazid MIC, indicated in
the column ‘acquired MIC’. MIC is expressed in terms of mg/L isoniazid. Mutation frequency is the
proportion of mutants. No. of DkatG is the number of katG deletion mutants. No. of targeted mutations is
the number of katG-S315T or inhA-C(-)15T found in the characterized mutants.
aDNA samples were derived from mutants pooled in sets of four.
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katG, was deleted from the RB14H5 genome [Table S2, avail-
able as Supplementary data at JAC Online (http://jac.oxfordjour-
nals.org/), and Figure S1]. The exact location of the deletion,
2127129–2176164, was determined by sequencing of this PCR
product.
Additional SNPs were accumulated during in vitro selection
With the data obtained by CGH, not only the extent of the katG
deletion could be determined, but also other mutations through-
out the genome of strain RB14H5 could be identiﬁed. The two
previously identiﬁed mutations in rpoB conferring resistance to
rifampicin and rifabutin, S522L and V176F, respectively,
35,36
were conﬁrmed by CGH. In addition, three single nucleotide
polymorphisms (SNPs) were identiﬁed in genes MT1253,
MT0208 and MT0516, corresponding to genes Rv1215c,
Rv198c and Rv0498 in H37Rv (GenBank AL123456), respect-
ively. PCR and sequencing of these regions in RB14H5 con-
ﬁrmed a C!T mutation in MT1253, a G!A mutation in
MT0208 and a C!G mutation in MT0516, of which only the
mutation in MT1253 was non-synonymous (Figure 2).
The regions where mutations were identiﬁed in RB14H5
were screened in the intermediate strains isolated after each anti-
biotic selection step, to determine when these additional
mutations occurred. After selection with rifampicin, two SNPs,
in MT1253 and MT0208, were identiﬁed in addition to the
mutation in rpoB. Selection with rifabutin resulted only in a
resistance-conferring mutation, rpoB-V176F, but the 49 kbp
deletion was accompanied by the mutation in MT0516 after
selection with isoniazid (Figure 2).
Discussion
Despite the increasing prevalence of resistant M. tuberculosis,
isoniazid remains an essential component of current TB treat-
ment programmes. In an attempt to shed more light on the mol-
ecular mechanisms leading to the development of MDR-TB, we
initially screened in vitro-selected isoniazid-resistant mutants of
M. tuberculosis strain MTB72, using different concentrations of
isoniazid. None of the characterized strains carried the mutations
that are predominantly responsible for isoniazid resistance in
clinical isolates [katG-S315T or inhA-C(-)15T]. Moreover, a
large proportion of the resistant clones acquired resistance to iso-
niazid by deletion of katG, a genotype that is rarely observed in
clinical isolates. In agreement with a previous report,
37 we
measured a higher mutation rate for isoniazid resistance than for
rifampicin resistance in vitro. However, the dramatic difference
between the in vivo and in vitro spectrum of isoniazid resistance
mutations suggests that an in vivo mutation rate for isoniazid
resistance equal to or potentially lower than the rifampicin
resistance rate ( 10
28 mutations/cell division) is much more
feasible. These ﬁndings indicate the importance of genetic
characterization of mutants before results obtained in the
laboratory are extrapolated to the clinical setting.
KatG protects bacteria from the oxidative burst encountered
when M. tuberculosis cells reside in macrophages or granu-
loma.
18,38 In vitro conditions are signiﬁcantly less challenging,
not in the least because of the extracellular catalases in the
medium, protecting the bacteria from harmful reactive oxygen
species. We speculated that these protective culture conditions
allowed for the observed high in vitro prevalence of DkatG
mutants, which are highly resistant to isoniazid, but susceptible
to oxidative insult.
28,31,38 However, addition of 50 mM H2O2 did
not alter the spectrum of mutations (Table 2). Attempts to select
isoniazid-resistant mutants from mycobacteria grown in medium
without added catalase have been unsuccessful, as bacterial
growth of the wild-type strain MTB72 was inadequate in
medium without catalase.
Conditions that seemed to have an effect on the proportion of
katG deletion mutants, but not on the presence of katG-S315T
or inhA-C(-)15T mutants, were selection of mutants with low
levels of isoniazid (0.4–2.0 mg/L, Tables 2 and 3) and growth/
selection in human macrophages. The average proportion of
DkatG mutants selected with 20 mg/L was 65% (39/60), with
1 mg/L was 55% (42/77) and with 0.4 mg/L was 28% (8/29,
Tables 2 and 3), suggesting that DkatG mutants are more likely
to be highly resistant.
Moreover, from the mutants selected with 0.4 mg/L isoniazid
that had an MIC between 0.4 and 2.0 mg/L, only 10% (3/30,
Table 3) had a deletion in the katG region. Growth in THP1
cells reduced the proportion of deletion mutants, selected with
1 mg/L isoniazid, to 20% (12/59, Table 2). These results show
that it is possible to reduce the proportion of deletion mutants
under speciﬁc conditions, but even in strains selected under
these conditions neither of the two most prevalent clinical
mutations were identiﬁed.
The mutants selected with 0.4 mg/L isoniazid (Table 3) that
were stratiﬁed on the basis of their MICs were all originally
selected on the same plate. In total, 179 isolates selected with
0.4 mg/L isoniazid (29þ30þ120, Table 3) were analysed by
MLPA from this plate. None of these 179 isolates acquired
either of the targeted mutations; thus, the prevalence of these
8 mg/L RFB 8 mg/L RIF  MTB72  R190 R190 RB14 RB14 RB14H5 RB14H5 20 mg/L INH 
1. rpoB-S522L 
2. MT1253: 
1358205 CAT(P) > TAT(Y) 
3. MT0208: 
234715 GAC(D) > GAT(D) 
5. 49 kbp del. 
    MT1928 - MT1976 
6. MT0516: 
588685 GTC(V) > GTG(V) 
4. rpoB-V176F 
Figure 2. Schematic representation of the three rounds of antibiotic selection that strain MTB72 was subjected to. The selection steps ﬁnally resulted in the
triple-resistant strain RB14H5. The position of the drug resistance-conferring mutations (1, 4 and 5) and additional mutations (2, 3 and 6) indicates in which
selection step they were acquired. Gene ID and coordinates of mutations 2, 3, 5 and 6 are based on the annotated genome sequence of strain CDC1551
(GenBank AE000516). R190 and RB14 are the names of the intermediate strains. RIF, rifampicin; RFB, rifabutin; INH, isoniazid; kbp, kilobase pairs;
del., deletion.
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under the conditions described. Similar results were also
obtained with strain H37Rv (,3.3%), suggesting that this is a
general phenomenon, rather than a strain-speciﬁc effect. This
observation is also supported by the absence of reports of spon-
taneous in vitro isoniazid-resistant mutants that carry clinical
mutations. In fact, we are aware of only one study that reports
the selection of an isoniazid-resistant katG-S315T mutant,
21 but
this mutant was acquired after a mouse was infected and treated
with isoniazid. It is possible that none of the selection conditions
we used were suitable for the selection of the targeted mutations,
perhaps because further adaptation is required to obtain an
MIC.0.4 mg/L. However, this would be true for all previous
reports of in vitro studies.
The general assumption is that isoniazid resistance in vivo is
much more widespread due to a higher mutation rate, particularly
in katG.
39 Indeed, the M. tuberculosis katG gene is located within
a genetically unstable region,
40 suggesting an increased propensity
for mutation. Based on this instability, one would expect to
observe a whole spectrum of katG mutations in resistant clinical
isolates, but in practice the majority of clinically resistant strains
contain the same mutations. However, the genetic instability of the
katG region is a likely explanation for the high prevalence of
DkatG mutants in our and other laboratory studies.
The empirical evidence for the high mutation rate hypothesis
is extracted from a few studies in which ﬂuctuation assays with
isoniazid were performed.
37 These studies report a signiﬁcantly
higher mutation rate for isoniazid compared with that for rifam-
picin, although mutants were not genetically characterized. We
obtained similar results for the in vitro mutation rates when
selecting with isoniazid and rifampicin (Table 2). However, we
suspect that this does not explain the high prevalence of isonia-
zid resistance in vivo, since none of the isoniazid-resistant
mutants we screened carried the mutations that are most fre-
quently observed in clinical isolates. In fact, merely two or three
mutations account for isoniazid resistance in the majority of
resistant clinical isolates.
8–13For rifampicin resistance there are
three rpoB mutations that are seen in 80%–95% of clinical
isolates.
9,41243 The in vivo mutation rate for isoniazid resistance
is therefore more likely to be similar to or lower than the rate
for rifampicin resistance, as was also suggested by others.
44 This
would still lead to a higher prevalence of isoniazid-
monoresistant isolates if one takes into account that isoniazid
has been used to treat TB much longer than rifampicin. In
addition, isoniazid has been regularly administered as monother-
apy, whereas rifampicin is almost exclusively part of a combi-
nation therapy, thereby reducing the chances of drug resistance.
Previously, researchers have shown that a whole spectrum of
different DkatG mutants can be found both in vitro and
in vivo.
13,15,40,45 In our study, partial deletions of the katG gene
close to the 50 terminus would not have been detected with the
methods used, possibly resulting in an underestimation of the del-
etion mutants present. The few in vitro studies on isoniazid resist-
ance that have been performed have indeed determined that the
majority of the mutants were catalase-negative.
45 Furthermore,
one group of researchers have implicitly stated that almost all
in vitro isoniazid mutants identiﬁed in their laboratory were
DkatG strains, regardless of the concentrations of isoniazid
used.
44
Throughout the course of this work, only two isoniazid-
resistant mutants were identiﬁed that contained point mutations
in the katG gene: one mutant acquired a TGG(W)!CGG(F)
mutation in codon 321; and the other an ACT(T)!ATT(I)
mutation in codon 271. Neither of these mutations has been
observed in clinical isolates, although other mutations in codon
321 have been reported and associated with very low quantities
of KatG, and, therefore, signiﬁcantly reduced catalase/peroxi-
dase activity.
7,16,22
None of our selected isoniazid-resistant strains carried a
mutation in the oxyR-ahpC intergenic region, even after
exposure to H2O2. Sherman et al.
28 suggested that either a
second selection event or passaging was probably necessary for
in vitro-generated mutants to acquire the additional mutation in
oxyR-ahpC. This may, in part, explain why this mutation was
not identiﬁed in any of our strains, although there is at least one
report of an isoniazid-resistant mutant that had acquired a
mutation in oxyR-ahpC in vitro.
46
The failure to detect any of the clinically prevalent mutations
in katG, inhA or ahpC in our study, in combination with results
of others, suggests that the current in vitro model is not repre-
sentative of the in vivo situation. These observations also argue
against the view that the primary route to MDR-TB is invariably
via isoniazid monoresistance. In fact, there is evidence that iso-
niazid resistance does not always precede rifampicin resistance
in the development of MDR in clinical settings.
In a recent report, a rifampicin-monoresistant M. tuberculosis
strain was disseminated and subsequently acquired isoniazid and
other drug resistance via the common resistance mechanisms,
including katG-S315T.
47 Moreover, a recent outbreak in London
started with an isoniazid-resistant strain, but upon dissemination
the strain acquired rifampicin resistance via unusual mutations
in rpoB.
48 This is interesting as the genetic background of bac-
teria probably plays a role in the evolutionary routes they can
and will follow. The presence of pre-existing drug resistance
mutations can be of inﬂuence on the acquisition of additional
drug resistance
36 and several studies have shown that different
genotypes of M. tuberculosis appear to have different preferred
resistance mechanisms.
12,13,49–51 Similar observations were
made in our laboratory and by others.
35,52 The occurrence of
atypical drug resistance mutations may therefore be an indication
of suboptimal genetic routes or unusual conditions.
We used CGH to compare the genomes of triple-resistant
strain RB14H5 and that of its wild-type parent strain, MTB72.
Earlier, we had determined that RB14H5 has a non-functioning
catalase–peroxidase in addition to a double mutation in rpoB,
which moderately increases the stress levels.
36 Remarkably,
strain RB14H5 had acquired a 49 kbp deletion, spanning 47
genes including the complete katG gene, but nonetheless it
remained viable in vitro. We are aware of only one other report
of a strain with an equally large deletion in the katG region.
40
Strain RB14H5 acquired three other SNPs in addition to the
major deletion and the drug resistance mutations (Figure 2). It is
unknown if these SNPs are adaptive mutations or more opportu-
nistic ‘hitchhike’ mutations and whether results obtained are
representative of the in vivo situation.
The genetic analysis of bacteria is generally focused on
previously identiﬁed targets, such as genes involved with anti-
biotic resistance or repetitive sequences for ﬁngerprinting pur-
poses. One consequence of this bias is that additional mutations
elsewhere in the genome are missed. Isogenic strains generated
in the laboratory may not be as isogenic as assumed and new
phenotypes may consequently be attributed to the wrong
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53 CGH allows the whole genome to be screened for
additional mutations that may have occurred in a strain of inter-
est compared with the wild-type template. It would be interest-
ing to compare clinical strains in this fashion, for instance
sequential isolates obtained from a single patient.
Additionally, CGH can be valuable in detecting drug
resistance-conferring mutations;
54 in some geographical
locations up to 25% of clinical strains have acquired isoniazid
resistance via unidentiﬁed mechanisms.
10,13,39,43
The present study shows that characterization of in vitro
mutants is essential in order to draw accurate conclusions and
that results obtained in the laboratory are not automatically
applicable to the in vivo situation. Combined MLPA and CGH
analysis of representative clinical isolates should be used to elu-
cidate preferred routes to MDR. Based on our results it can be
concluded that the high in vitro mutation rate for isoniazid
resistance is not a satisfactory explanation for the widespread
isoniazid resistance found in clinical isolates, as there is no sub-
stantial evidence that the in vivo mutation rate for isoniazid
resistance is signiﬁcantly higher than that for rifampicin resist-
ance. Moreover, the outcomes of our study in combination with
reports of others lead us to question the current view that devel-
opment of a successful MDR strain predominantly begins with
isoniazid monoresistance. A more detailed study of the genetic
mechanisms by which M. tuberculosis strains adapt to their
environment is warranted, hopefully leading to identiﬁcation of
genotypes or drug resistance proﬁles that are most likely to
result in virulent strains.
Acknowledgements
We would like to thank MRC-Holland (Amsterdam, The
Netherlands) for providing all MLPA reagents and the RIVM
(Bilthoven, The Netherlands) for providing us with strain
H37Rv. We also thank Dr Arend Kolk and Sjoukje Kuijper for
help with the macrophage growth experiments.
Funding
This work was partly funded by the EU 6th Framework
Programme TBAdapt (project no. 037919).
Transparency declarations
None to declare.
Supplementary data
Table S1, Table S2 and Figure S1 are available as Supplementary
data at JAC Online (http://jac.oxfordjournals.org/).
References
1. World Health Organization. Anti-tuberculosis Drug Resistance in
the World. Report No. 4. Geneva: WHO, 2008; WHO/HTM/TB/
2008.394.
2. Middlebrook G. Isoniazid-resistance and catalase activity of
tubercle bacilli. Am Rev Tuberc 1954; 69: 471–2.
3. Zhang Y, Heym B, Allen B et al. The catalase–peroxidase gene
and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;
358: 591–3.
4. Altamirano M, Marostenmaki J, Wong A et al. Mutations in the
catalase–peroxidase gene from isoniazid-resistant Mycobacterium
tuberculosis isolates. J Infect Dis 1994; 169: 1162–5.
5. Stoeckle MY, Guan L, Riegler N et al. Catalase–peroxidase
gene sequences in isoniazid-sensitive and -resistant strains of
Mycobacterium tuberculosis from New York City. J Infect Dis 1993;
168: 1063–5.
6. Goto M, Oka S, Tachikawa N et al. KatG sequence deletion is
not the major cause of isoniazid resistance in Japanese and Yemeni
Mycobacterium tuberculosis isolates. Mol Cell Probes 1995; 9: 433–9.
7. Rouse DA, DeVito JA, Li Z et al. Site-directed mutagenesis of
the katG gene of Mycobacterium tuberculosis: effects on catalase–
peroxidase activities and isoniazid resistance. Mol Microbiol 1996; 22:
583–92.
8. Herrera-Leo ´n L, Molina T, Saı ´zPet al. New multiplex PCR for
rapid detection of isoniazid-resistant Mycobacterium tuberculosis clini-
cal isolates. Antimicrob Agents Chemother 2005; 49: 144–7.
9. Van Rie A, Warren R, Mshanga I et al. Analysis for a limited
number of gene codons can predict drug resistance of Mycobacterium
tuberculosis in a high-incidence community. J Clin Microbiol 2000; 39:
636–41.
10. Zhang M, Yue J, Yang YP et al. Detection of mutations associ-
ated with isoniazid resistance in Mycobacterium tuberculosis isolates
from China. J Clin Microbiol 2005; 43: 5477–82.
11. Dalla Costa ER, Ribeiro MO, Silva MS et al. Correlations of
mutations in katG, oxyR-ahpC and inhA genes and in vitro suscepti-
bility in Mycobacterium tuberculosis clinical strains segregated by spoli-
gotype families from tuberculosis prevalent countries in South America.
BMC Microbiol 2009; 9: 39.
12. Gagneux S, Burgos MV, DeRiemer K et al. Impact of bacterial
genetics on the transmission of isoniazid-resistant Mycobacterium
tuberculosis. PLoS Pathog 2006; 2: e61.
13. Hazbo ´n MH, Brimacombe M, Bobadilla del Valle M et al.
Population genetics study of isoniazid resistance mutations and evol-
ution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob
Agents Chemother 2006; 50: 2640–9.
14. Wengenack NL, Uhl JR, St Amand AL et al. Recombinant
Mycobacterium tuberculosis KatG(S315T) is a competent catalase–
peroxidase with reduced activity toward isoniazid. J Infect Dis 1997;
176: 722–7.
15. Coll P, Arago ´n LM, Alcaide F et al. Molecular analysis of isonia-
zid and rifampin resistance in Mycobacterium tuberculosis isolates
recovered from Barcelona. Microb Drug Resist 2005; 11: 107–14.
16. Mo L, Zhang W, Wang J et al. Three-dimensional model and
molecular mechanism of Mycobacterium tuberculosis catalase–
peroxidase (KatG) and isoniazid-resistant KatG mutants. Microb Drug
Resist 2004; 10: 269–79.
17. Saint-Joanis B, Souchon H, Wilming M et al. Use of site-directed
mutagenesis to probe the structure, function and isoniazid activation of
the catalase/peroxidase, KatG, from Mycobacterium tuberculosis.
Biochem J 1999; 338: 753–60.
18. Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on
the virulence of Mycobacterium tuberculosis and the implication for
transmission in humans. Infect Immun 2002; 70: 4955–60.
19. Li Z, Kelley C, Collins F et al. Expression of katG in
Mycobacterium tuberculosis is associated with its growth and persist-
ence in mice and guinea pigs. J Infect Dis 1998; 177: 1030–5.
20. Abe C, Kobayashi I, Mitarai S et al. Biological and molecular
characteristics of Mycobacterium tuberculosis clinical isolates with low-
Bergval et al.
522level resistance to isoniazid in Japan. J Clin Microbiol 2008; 46:
2263–8.
21. Guo H, Seet Q, Denkin S et al. Molecular characterization of
isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from
the USA. J Med Microbiol 2006; 55: 1527–31.
22. Heym B, Alzari PM, Honore ´ N et al. Missense mutations in the
catalase–peroxidase gene, katG, are associated with isoniazid resist-
ance in Mycobacterium tuberculosis. Mol Microbiol 1994; 15: 235–45.
23. Ramaswamy SV, Reich R, Dou SJ et al. Single nucleotide poly-
morphisms in genes associated with isoniazid resistance in
Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:
1241–50.
24. Marttila HJ, Soini H, Huovinen P et al. katG mutations in
isoniazid-resistant Mycobacterium tuberculosis isolates recovered from
Finnish patients. Antimicrob Agents Chemother 1996; 40: 2187–9.
25. Van Soolingen D, de Haas PE, van Doorn HR et al. Mutations at
amino acid position 315 of the katG gene are associated with high-level
resistance to isoniazid, other drug resistance, and successful trans-
mission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis
2000; 182: 1788–90.
26. van Doorn HR, de Haas PE, Kremer K et al. Public health
impact of isoniazid-resistant Mycobacterium tuberculosis strains with a
mutation at amino-acid position 315 of katG: a decade of experience in
The Netherlands. Clin Microbiol Infect 2006; 12: 769–75.
27. Kelley CL, Rouse DA, Morris SL. Analysis of ahpC gene
mutations in isoniazid-resistant clinical isolates of Mycobacterium
tuberculosis. Antimicrob Agents Chemother 1997; 41: 2057–8.
28. Sherman DR, Mdluli K, Hickey MJ et al. AhpC, oxidative stress
and drug resistance in Mycobacterium tuberculosis. Biofactors 1999;
10: 211–7.
29. Dhandayuthapani S, Zhang Y, Mudd MH et al. Oxidative stress
response and its role in sensitivity to isoniazid in mycobacteria: charac-
terization and inducibility of ahpC by peroxides in Mycobacterium
smegmatis and lack of expression in M. aurum and M. tuberculosis.
J Bacteriol 1996; 178: 3641–9.
30. Wilson TM, Collins DM. ahpC, a gene involved in isoniazid
resistance of the Mycobacterium tuberculosis complex. Mol Microbiol
1996; 19: 1025–34.
31. Sherman DR, Mdluli K, Hickey MJ et al. Compensatory ahpC
gene expression in isoniazid-resistant Mycobacterium tuberculosis.
Science 1996; 272: 1641–3.
32. Sreevatsan S, Pan X, Zhang Y et al. Analysis of the oxyR-ahpC
region in isoniazid-resistant and -susceptible Mycobacterium
tuberculosis complex organisms recovered from diseased humans and
animals in diverse localities. Antimicrob Agents Chemother 1997; 41:
600–6.
33. Bergval IL, Vijzelaar RN, Dalla Costa ER et al. Development
of multiplex assay for rapid characterization of Mycobacterium
tuberculosis. J Clin Microbiol 2008; 46: 689–99.
34. Luria SE, Delbru ¨ck M. Mutations of bacteria from virus sensitivity
to virus resistance. Genetics 1943; 28: 491–511.
35. Anthony RM, Schuitema AR, Bergval IL et al. Acquisition of rifa-
butin resistance by a rifampicin resistant mutant of Mycobacterium
tuberculosis involves an unusual spectrum of mutations and elevated
frequency. Ann Clin Microbiol Antimicrob 2005; 4:9 .
36. Bergval IL, Klatser PR, Schuitema AR et al. Speciﬁc mutations
in the Mycobacterium tuberculosis rpoB gene are associated with
increased dnaE2 expression. FEMS Microbiol Lett 2007; 275: 338–43.
37. David HL. Probability distribution of drug-resistant mutants in
unselected populations of Mycobacterium tuberculosis. Appl Microbiol
1970; 20: 810–4.
38. Manca C, Paul S, Barry CE III et al. Mycobacterium tuberculosis
catalase and peroxidase activities and resistance to oxidative killing in
human monocytes in vitro. Infect Immun 1999; 67:7 4– 9 .
39. Riska PF, Jacobs WR, Alland D. Molecular determinants of drug
resistance in tuberculosis. Int J Tuberc Lung Dis 2000; 4: S4–S10.
40. Zhang Y, Young D. Strain variation in the katG region of
Mycobacterium tuberculosis. Mol Microbiol 1994; 14: 301–8.
41. Telenti A. Genetics of drug resistance in tuberculosis. Clin Chest
Med 1997; 18: 55–64.
42. Sajduda A, Brzostek A, Poplawska M et al. Molecular character-
ization of rifampin- and isoniazid-resistant Mycobacterium tuberculosis
strains isolated in Poland. J Clin Microbiol 2004; 42: 2425–31.
43. Ramaswamy S, Musser JM. Molecular genetic basis of antimi-
crobial agent resistance in Mycobacterium tuberculosis: 1998 update.
Tuber Lung Dis 1998; 79: 3–29.
44. Slayden RA, Barry CE III. The genetics and biochemistry of
isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect
2000; 2: 659–69.
45. Mdluli K, Swanson J, Fischer E et al. Mechanisms involved in
the intrinsic isoniazid resistance of Mycobacterium avium. Mol
Microbiol 1998; 27: 1223–33.
46. Heym B, Stavropoulos E, Honore ´ N et al. Effects of overexpres-
sion of the alkyl hydroperoxide reductase AhpC on the virulence and
isoniazid resistance of Mycobacterium tuberculosis. Infect Immun
1997; 65: 1395–401.
47. Bifani P, Mathema B, Kurepina N et al. The evolution of drug
resistance in Mycobacterium tuberculosis: from a mono-rifampin-
resistant cluster into increasingly multidrug-resistant variants in an
HIV-seropositive population. J Infect Dis 2008; 198:9 0–4 .
48. Jenkins C, Claxton AP, Shorten RJ et al. Rifampicin resistance
in tuberculosis outbreak, London, England. Emerg Infect Dis 2005; 11:
931–4.
49. Lipin MY, Stepanshina VN, Shemyakin IG et al. Association of
speciﬁc mutations in katG, rpoB, rpsL and rrs genes with spoligotypes
of multidrug-resistant Mycobacterium tuberculosis isolates in Russia.
Clin Microbiol Infect 2007; 13: 620–6.
50. Hillemann D, Kubica T, Ru ¨sch-Gerdes S et al. Disequilibrium in
distribution of resistance mutations among Mycobacterium tuberculosis
Beijing and non-Beijing strains isolated from patients in Germany.
Antimicrob Agents Chemother 2005; 49: 1229–31.
51. Rinder H, Dobner P, Feldmann K et al. Disequilibria in the distri-
bution of rpoB alleles in rifampicin-resistant M. tuberculosis isolates
from Germany and Sierra Leone. Microb Drug Resist 1997; 3: 195–7.
52. O’Sullivan DM, McHugh TD, Gillespie SH. The effect of oxi-
dative stress on the mutation rate of Mycobacterium tuberculosis with
impaired catalase/peroxidase function. J Antimicrob Chemother 2008;
62: 709–12.
53. Chakravorty S, Aladegbami B, Motiwala AS et al. Rifampin
resistance, Beijing-W clade-single nucleotide polymorphism cluster
group 2 phylogeny, and the Rv2629 191-C allele in Mycobacterium
tuberculosis strains. J Clin Microbiol 2008; 46: 2555–60.
54. Manjunatha UH, Boshoff H, Dowd CS et al. Identiﬁcation of a
nitroimidazo-oxazine-speciﬁc protein involved in PA-824 resistance in
Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103:
431–6.
M. tuberculosis and isoniazid resistance
523